Skip to content

PAMNEU - Memory in Neurology

PAMNEU: Easy Detection of Memory Disorders Using Very Short ALBA and PICNIR Tests in Neurological Outpatient Clinics in the Czech Republic

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06154564
Enrollment
600
Registered
2023-12-04
Start date
2023-11-01
Completion date
2026-05-31
Last updated
2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment

Keywords

Cognitive Impairment, Outpatient Neurologic Service, Population Distribution

Brief summary

Memory in Neurology project (PAMNEU) aims to map the distribution and severity of cognitive impairment in patients of outpatient neurologic offices across the geographical area of the Czech Republic. 1000 patients in 50 neurologic offices will undergo cognitive tests (ALBA and PICNIR) and psychometric scales (FAQ-CZ and GDS-CZ) to asses their functional state and depressive symptoms. The trial's primary goal is to assess the distribution of cognitive impairment among diagnostic groups in neurologic care according to the ICD-10. Additionally, the feasibility of ALBA and PICNIR methods to uncover previously undiagnosed cognitive impairments will be evaluated.

Interventions

None listed

Sponsors

Charles University, Czech Republic
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Dispensarization of at least six months in an outpatient neurologic office with an ICD-10 diagnosis * Age\>=50 * Permanent residency in the geographical area of the Czech Republic

Exclusion criteria

* Diagnosis of mental retardation (F70-F79) according to ICD-10 * Refusal to sign the informed consent and consent with GDPR * Uncorrected visual impairment * Uncorrected auditory impairment * Impairment of hand movement preventing the patient from filling in the questionnaires. * Inability to participate in the project

Design outcomes

Primary

MeasureTime frameDescription
Baseline ALBAEstablished on Day 0 as a single assessment.Amnesia Light and Brief Assessment (ALBA) test is an innovative method to assess cognitive functions quickly. The cognitive performance is scaled as an overall score between 0-12 (a lower value denotes a more severe cognitive impairment).
Baseline PICNIREstablished on Day 0 as a single assessment.Picture Naming and Immediate Recall test (PICNIR) is an innovative test method to assess cognitive functions quickly. The cognitive performance is scaled as an overall score between 0-20 (a lower value denotes a more severe cognitive impairment).
Statistical analysis of ALBA resultsThe final statistical analysis will be performed through study completion, an average of 6 months.Statistical analysis of ALBA results compared to groups determined by ICD-10 diagnosis and demographical data.
Statistical analysis of PICNIR resultsThe final statistical analysis will be performed through study completion, an average of 6 months.Statistical analysis of PICNIR results compared to groups determined by ICD-10 diagnosis and demographical data.

Secondary

MeasureTime frameDescription
Baseline FAQ-CZEstablished as a baseline on Day 0.Functional Activities Questionnaire - Czech version (FAQ-CZ) is a standardized questionnaire administered to assess a patient´s functional state regarding daily activities. Ten items of daily functioning are scaled between 0-3 (a higher value denotes a higher dependency) to reach the overall score between 0-30 (a higher value denotes a higher dependency). This version of the scale will be used for participants´ self-evaluation.
Baseline GDS-CZEstablished as a baseline on Day 0.The Geriatric Depression Scale - Czech version (GDS-CZ) is a standardized questionnaire administered to assess depressive symptoms, particularly in the elderly population. Fifteen items are scaled between 0-1 to reach the overall score between 0-15 (a higher value denotes a higher level of depressive symptoms).

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026